Definition: „Microbiomics“ means the scientific analysis of the microbiomes.

The advent of latest generation sequencing technology is now making it possible to explore the impact of colonizing microbial communities (microbiomes) in the various human body compartments on individual disease risk. Importantly, an individual’s microbiomes may be potentially modifiable by simple dietary, lifestyle or pharmacological interventions, potentially opening new doors to primary, secondary and tertiary prevention. The prospective population- and patient-based cohorts of iMed will offer powerful resources to address the impact of human microbiomes on initiation, progression and outcome of the chronic noncommunicable diseases to be studied by the iMed partners. Prospective study designs will make it possible to address questions of cause and effect and sequential events.

iMed will help to:

  • Assess the role(s) of human microbiomes in the evolution and progression of neurodegeneration/dysfunction, colon CA, cardiovascular disease, periodontal disease, metabolic dysfunction, and acute bacterial infections;
  • Study changes in human microbiomes due to exposure to antibiotic treatments;
  • To develop and establish metatranscriptomics tools to characterize functional changes in gene expression in the microbiomes.

HZI: Robert Geffers, Andrew Oxley, Frank Pessler, Dietmar Pieper, Michael Reck, Irene Wagner-Döbler


to top